Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15197232 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2HSD17B10RAB9ALMNAALDH1A1 | |
| SCHEMBL15100731 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2HSD17B10RAB9ALMNATSHR | |
| SCHEMBL256812 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2HSD17B10RAB9ALMNATSHR | |
| SCHEMBL16280257 | 0.75 | ALDH1A1 (0.52) | HSD17B10LMNATSHRALDH1A1KDM4E | |
| SCHEMBL257537 | 0.73 | NPC1 (0.42) | SMN1; SMN2RAB9ANPC1ALDH1A1GAA | |
| SCHEMBL4803986 | 0.72 | MAOB (0.49) | SMN1; SMN2HSD17B10RAB9ANPC1MAOB | |
| SCHEMBL256814 | 0.72 | SMN1; SMN2 (0.40) | SMN1; SMN2HSD17B10RAB9ALMNATSHR | |
| SCHEMBL257529 | 0.70 | CTNNB1 (0.51) | SMN1; SMN2RAB9ALMNANPC1ALDH1A1 | |
| SCHEMBL526662 | 0.70 | SMN1; SMN2 (0.58) | SMN1; SMN2HSD17B10RAB9ANPC1ALDH1A1 | |
| SCHEMBL28703128 | 0.70 | MAOB (0.47) | SMN1; SMN2HSD17B10RAB9ANPC1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895552-B2 | Cyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2612848-A1 | CYCLIC AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029942-A1 | CYCLIC AMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | HDAC10, H1-10, H1-0 | SMN1; SMN2 2704/4885HSD17B10 146/4885RAB9A 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.